Reversal of warfarin-induced anticoagulation with factor VIIa prior to rt-PA in acute stroke

Neurology

Volumn 64, Issue 8, 2005, Pages 1480-1481

  Talkad, A ^a,b   Mathews, M ^a   Honings, D ^a   Jahnel, J ^a   Wang, D ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b OSF SAINT FRANCIS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; WARFARIN;

AGED; ARTICLE; BLOOD CLOTTING DISORDER; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG INDUCED DISEASE; FEMALE; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME;

EID: 17644367165     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000158683.20315.2A     Document Type: Article

References (3)

1. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coag Fibrinol 2003;14:469-477.
2. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994;55:638-648.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.